Specific eligibility criteria must be met, these include:

• There is no satisfactory alternative treatment for the patient including approved standard of care treatments for their multiple myeloma; and
• There is reason to believe that the benefit to the patient using belantamab mafodotin outweighs the risk
• Patient does not qualify for, or is unable to participate in, other ongoing clinical trials

INCLUSION CRITERIA:

• Written informed consent
• Diagnosis of multiple myeloma and/or plasma cell dyscrasias and either:
  • For combination with bortezomib/dexamethasone; previously treated with at least 1 prior line of MM therapy and must have documented disease progression during or after their most recent therapy OR
  • For combination with pomalidomide/dexamethasone; have been previously treated with at least 1 prior line of MM therapy including a lenalidomide-containing regimen (lenalidomide must have been administered for at least 2 consecutive cycles) and must have documented disease progression during or after their most recent therapy.
• Able to obtain ophthalmic examinations at baseline, before the next 3 subsequent treatment cycles and as clinically indicated on treatment
• Contraception requirements
  • • Female Participants: A female patient is eligible to participate if one of the following conditions applies:
      • The patient Is not a woman of childbearing potential (WOCBP) OR II. The patient Is a WOCBP and using an effective contraceptive method during treatment with belantamab mafodotin and for 4 months after the last dose. The patient must also have a negative highly sensitive serum pregnancy test within 72 hours of dosing on Cycle 1 Day 1. Please discuss with GSK physician if the patient is pregnant, breast-feeding or planning to have a baby.
      • Male participants with female partners of child-bearing potential are eligible to participate if they agree to use effective contraception during treatment with belantamab mafodotin until 6 months after the last dose

EXCLUSION CRITERIA:

• If considering combination with bortezomib/dexamethasone intolerant or refractory to bortezomib. If considering combination with pomalidomide/dexamethasone intolerant or refractory to pomalidomide
• Alanine transaminase (ALT) >2.5x upper limit of normal (ULN).
• Total bilirubin >1.5xULN; patients with Gilbert's syndrome can be included with total bilirubin >1.5xULN as long as direct bilirubin is ≤1.5xULN.
• Cirrhosis or current unstable liver or biliary disease per physician assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, esophageal or gastric varices, persistent jaundice.
• Patients with Hepatitis B will be excluded unless:
  • HbcAb positive, HBsAg negative: HBV deoxyribonucleic acid (DNA) undetectable and Antiviral treatment instituted if HBV DNA becomes detectable
  • HBsAg positive at screen or within 3 months prior to first dose: HBV DNA undetectable and Antiviral treatment maintained throughout program treatment
• Patients with positive hepatitis C antibody test result or positive hepatitis C ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of program treatment unless:
• • RNA test negative
  • Successful anti-viral treatment followed by a negative HCV RNA test after a washout period of at least 4 weeks
• Evidence of Active Bleeding requiring intervention
• Currently Active Graft-versus-host disease (GvHD)
• Known Hypersensitivity to the active substance or to any of the excipients
• Previous progression on belantamab mafodotin
• Active infection requiring treatment
• Previous participation in DREAMM-7 or DREAMM-8 clinical trials